These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 20021445)

  • 1. Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome.
    Coll T; Rodrïguez-Calvo R; Barroso E; Serrano L; Eyre E; Palomer X; Vázquez-Carrera M
    Curr Mol Pharmacol; 2009 Jan; 2(1):46-55. PubMed ID: 20021445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of PPARβ/δ in the management of metabolic syndrome and its associated cardiovascular complications.
    Benetti E; Patel NS; Collino M
    Endocr Metab Immune Disord Drug Targets; 2011 Dec; 11(4):273-84. PubMed ID: 21696362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases.
    Bedu E; Wahli W; Desvergne B
    Expert Opin Ther Targets; 2005 Aug; 9(4):861-73. PubMed ID: 16083348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) acts as regulator of metabolism linked to multiple cellular functions.
    Wagner KD; Wagner N
    Pharmacol Ther; 2010 Mar; 125(3):423-35. PubMed ID: 20026355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PPARβ/δ for the treatment of type 2 diabetes mellitus.
    Salvadó L; Serrano-Marco L; Barroso E; Palomer X; Vázquez-Carrera M
    Expert Opin Ther Targets; 2012 Feb; 16(2):209-23. PubMed ID: 22280315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GQ-130, a novel analogue of thiazolidinedione, improves obesity-induced metabolic alterations in rats: Evidence for the involvement of PPARβ/δ pathway.
    Silva OA; Ribeiro-Filho HV; Avelino TM; Tittanegro TH; Figueira ACM; Rabelo LA; Pitta IDR; Lahlou S; Duarte GP
    Clin Exp Pharmacol Physiol; 2020 May; 47(5):798-808. PubMed ID: 31909493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders.
    Palomer X; Barroso E; Pizarro-Delgado J; Peña L; Botteri G; Zarei M; Aguilar D; Montori-Grau M; Vázquez-Carrera M
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29558390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementary Immunometabolic Effects of Exercise and PPARβ/δ Agonist in the Context of Diet-Induced Weight Loss in Obese Female Mice.
    Le Garf S; Murdaca J; Mothe-Satney I; Sibille B; Le Menn G; Chinetti G; Neels JG; Rousseau AS
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR delta: a dagger in the heart of the metabolic syndrome.
    Barish GD; Narkar VA; Evans RM
    J Clin Invest; 2006 Mar; 116(3):590-7. PubMed ID: 16511591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation.
    Bishop-Bailey D; Bystrom J
    Pharmacol Ther; 2009 Nov; 124(2):141-50. PubMed ID: 19615407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
    Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
    Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive effects of peroxisome proliferator-activated receptor-β/δ activation.
    Toral M; Romero M; Pérez-Vizcaíno F; Duarte J; Jiménez R
    Am J Physiol Heart Circ Physiol; 2017 Feb; 312(2):H189-H200. PubMed ID: 27881385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells.
    Alvarez-Guardia D; Palomer X; Coll T; Serrano L; Rodríguez-Calvo R; Davidson MM; Merlos M; El Kochairi I; Michalik L; Wahli W; Vázquez-Carrera M
    Biochim Biophys Acta; 2011 Feb; 1811(2):59-67. PubMed ID: 21070867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-mediated regulation of peroxisome proliferator-activated receptor (PPAR) beta/delta: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid.
    Rieck M; Meissner W; Ries S; Müller-Brüsselbach S; Müller R
    Mol Pharmacol; 2008 Nov; 74(5):1269-77. PubMed ID: 18701617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPARbeta/delta ligands as modulators of the inflammatory response.
    Kilgore KS; Billin AN
    Curr Opin Investig Drugs; 2008 May; 9(5):463-9. PubMed ID: 18465655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.
    Monsalve FA; Pyarasani RD; Delgado-Lopez F; Moore-Carrasco R
    Mediators Inflamm; 2013; 2013():549627. PubMed ID: 23781121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines.
    Hollingshead HE; Killins RL; Borland MG; Girroir EE; Billin AN; Willson TM; Sharma AK; Amin S; Gonzalez FJ; Peters JM
    Carcinogenesis; 2007 Dec; 28(12):2641-9. PubMed ID: 17693664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor β/δ induces myogenesis by modulating myostatin activity.
    Bonala S; Lokireddy S; Arigela H; Teng S; Wahli W; Sharma M; McFarlane C; Kambadur R
    J Biol Chem; 2012 Apr; 287(16):12935-51. PubMed ID: 22362769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.
    Jay MA; Ren J
    Curr Diabetes Rev; 2007 Feb; 3(1):33-9. PubMed ID: 18220654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells.
    Dressel U; Allen TL; Pippal JB; Rohde PR; Lau P; Muscat GE
    Mol Endocrinol; 2003 Dec; 17(12):2477-93. PubMed ID: 14525954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.